• Geoffrey F Joyce, Dana P Goldman, Pinar Karaca-Mandic, and Grant D Lawless.
• RAND Corporation, CA 90401, USA. gjoyce@rand.org
• Am J Manag Care. 2008 Dec 1; 14 (12): 821-8.

ObjectiveTo examine whether initiation of a biologic agent to treat 2 autoimmune disorders -- rheumatoid arthritis (RA) and multiple sclerosis (MS) -- affects use of other medical services.Study DesignLongitudinal analysis from 1997 to 2005 examining linked pharmacy and medical claims from large, private employers.MethodsThe study sample included 30,761 individuals newly diagnosed with RA (92,660 person-years) and 8961 unique individuals with MS (25,100 person-years). Negative binomial models were used to estimate changes in inpatient, outpatient, and procedure use before and after initiating a biologic drug for each condition.ResultsStarting a biologic response modifier was associated with a reduction in physician visits and use of expensive procedures for patients with RA within 2 to 3 years of initiation. Use of immunomodulatory therapy for MS was associated with a reduced number of hospitalizations and expensive procedures within 2 years of initiation. Although biologics may reduce other types of service use, the savings do not come close to offsetting the full cost of these drugs.ConclusionsGiven the high cost of many specialty drugs, health plans may rightly focus on making sure only patients who will most benefit receive them. But once such patients are identified, it makes little sense to limit coverage.

38 keywords...

hide…